Climate Change Data Portal
DOI | 10.1371/journal.pone.0056352 |
Increased Matrix Metalloproteinase (MMPs) Levels Do Not Predict Disease Severity or Progression in Emphysema | |
D'; Armiento, Jeanine M.1; Goldklang, Monica P.1; Hardigan, Andrew A.2; Geraghty, Patrick2; Roth, Michael D.3; Connett, John E.4; Wise, Robert A.5; Sciurba, Frank C.6; Scharf, Steven M.7; Thankachen, Jincy1; Islam, Monirul1; Ghio, Andrew J.8; Foronjy, Robert F.2 | |
发表日期 | 2013-02-18 |
ISSN | 1932-6203 |
卷号 | 8期号:2 |
英文摘要 | Rationale: Though matrix metalloproteinases (MMPs) are critical in the pathogenesis of COPD, their utility as a disease biomarker remains uncertain. This study aimed to determine whether bronchoalveolar lavage (BALF) or plasma MMP measurements correlated with disease severity or functional decline in emphysema. Methods: Enzyme-linked immunosorbent assay and luminex assays measured MMP-1, -9, -12 and tissue inhibitor of matrix metalloproteinase-1 in the BALF and plasma of non-smokers, smokers with normal lung function and moderate-to-severe emphysema subjects. In the cohort of 101 emphysema subjects correlative analyses were done to determine if MMP or TIMP-1 levels were associated with key disease parameters or change in lung function over an 18-month time period. Main Results: Compared to non-smoking controls, MMP and TIMP-1 BALF levels were significantly elevated in the emphysema cohort. Though MMP-1 was elevated in both the normal smoker and emphysema groups, collagenase activity was only increased in the emphysema subjects. In contrast to BALF, plasma MMP-9 and TIMP-1 levels were actually decreased in the emphysema cohort compared to the control groups. Both in the BALF and plasma, MMP and TIMP-1 measurements in the emphysema subjects did not correlate with important disease parameters and were not predictive of subsequent functional decline. Conclusions: MMPs are altered in the BALF and plasma of emphysema; however, the changes in MMPs correlate poorly with parameters of disease intensity or progression. Though MMPs are pivotal in the pathogenesis of COPD, these findings suggest that measuring MMPs will have limited utility as a prognostic marker in this disease. |
语种 | 英语 |
WOS记录号 | WOS:000315159200038 |
来源期刊 | PLOS ONE |
来源机构 | 美国环保署 |
文献类型 | 期刊论文 |
条目标识符 | http://gcip.llas.ac.cn/handle/2XKMVOVA/61778 |
作者单位 | 1.Columbia Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, New York, NY USA; 2.St Lukes Roosevelt Hlth Sci Ctr, Div Pulm & Crit Care Med, New York, NY 10032 USA; 3.Univ Calif Los Angeles, Div Pulm & Crit Care Med, Los Angeles, CA USA; 4.Univ Minnesota, Dept Biostat CCBR, St Paul, MN USA; 5.Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD USA; 6.Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA; 7.Univ Maryland, Div Pulm & Crit Care Med, Baltimore, MD 21201 USA; 8.US EPA, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA |
推荐引用方式 GB/T 7714 | D',Armiento, Jeanine M.,Goldklang, Monica P.,et al. Increased Matrix Metalloproteinase (MMPs) Levels Do Not Predict Disease Severity or Progression in Emphysema[J]. 美国环保署,2013,8(2). |
APA | D'.,Armiento, Jeanine M..,Goldklang, Monica P..,Hardigan, Andrew A..,Geraghty, Patrick.,...&Foronjy, Robert F..(2013).Increased Matrix Metalloproteinase (MMPs) Levels Do Not Predict Disease Severity or Progression in Emphysema.PLOS ONE,8(2). |
MLA | D',et al."Increased Matrix Metalloproteinase (MMPs) Levels Do Not Predict Disease Severity or Progression in Emphysema".PLOS ONE 8.2(2013). |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。